You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 5,618,916

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,618,916

Title:	Purified protein which functions as a mycobacterial receptor for fibronectin
Abstract:	A method for the treatment of superficial urinary tract tumors in a mammal involves administering a diagnostically effective amount of a liposomal composition comprising a liposome, a chemotherapeutic agent or immune activating drug carried by the liposome and a purified protein which functions as a mycobacterial receptor for fibronectin on the surface of the liposome whereby the liposomal composition becomes attached to and internalized in the cells of the tumors. In lieu of the purified protein an antibody to an integrin receptor on the surface of the cells of the tumors may be used or a delivery system composed of a conjugate of a chemotherapeutic agent or immune activating drug and an antibody to an integrin receptor may be employed.
Inventor(s):	Ratliff; Timothy J. (St. Louis, MO), Brown; Eric J. (St. Louis, MO)
Assignee:	The Jewish Hospital of St. Louis (St. Louis, MO)
Application Number:	08/265,450
Patent Claims:	1. A purified protein which functions as a mycobacterial receptor for fibronectin, said protein: (a) binding directly to fibronectin, said binding being inactivated by trypsin; (b) being essential for attachment of bacillus Calmette-Guerin to fibronectin; (c) binding directly to fibronectin-coated surfaces; (d) having a primary protein band at 55 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis on pooled fractions containing said purified protein; (e) inhibiting fibronectin attachment to bacillus Calmette-Guerin in a dose-dependent manner; (f) having a monoclonal antibody thereto which blocks the attachment of bacillus Calmette-Guerin to fibronectin-coated surfaces; and (g) having a polyclonal antibody that recognizes only the 55 kDa band in unfractionated bacterial extracts.

Details for Patent 5,618,916

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989	⤷ Try a Trial	2014-04-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.